The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study.
Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, Bloom DE, Wang C. · 2023
Read The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study. by Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, Bloom DE, Wang C. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10369014.txt.
Introduction
Chen and colleagues modelled the world cost of a chronic lung disease from 2020 to 2050. The disease is COPD, in which air flow out of the lungs slowly worsens. It is the third top cause of death in the world. The team built an economic model for 204 nations and areas.
Their model counts lost work from illness and death, plus care costs that drain savings. Chen puts the total loss at 4.326 trillion dollars over the 30 years. That is like a yearly tax of 0.111% on world output. China bears the largest share, at 1.363 trillion, with the USA next at 1.037 trillion. The team urges states to invest now to curb the disease.
Catalog record
| CREATOR | Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, Bloom DE, Wang C. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study By Simiao Chen, Michael Kuhn, Klaus Prettner, Fengyun Yu, Ting Yang, Till Bärnighausen, David E Bloom, Chen Wang Published in: The Lancet. Global Health DOI: 10.1016/S2214-109X(23)00217-6 ABSTRACT Summary Background Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide and imposes a substantial economic burden. Gaining a thorough understanding of the economic implications of COPD is an important prerequisite for sound, evidence-based policy making. We aimed to estimate the macroeconomic burden of COPD for each country and establish its distribution across world regions. Methods In this health-augmented macroeconomic modelling study we estimated the macroeconomic burden of COPD for 204 countries and territories over the period 2020–50. The model accounted for (1) the effect of COPD mortality and morbidity on labour supply, (2) age and sex specific differences in education and work experience among those affected by COPD, and (3) the impact of COPD treatment costs on physical capital accumulation. We obtained data from various public sources including the Global Burden of Disease Study 2019, the World Bank database, and the literature. The macroeconomic burden of COPD was assessed by comparing gross domestic product (GDP) between a scenario projecting disease prevalence based on current estimates and a counterfactual scenario with zero COPD prevalence from 2020 to 2050. Findings Our findings suggest that COPD will cost the world economy INT$4·326 trillion (uncertainty interval 3·327–5·516; at constant 2017 prices) in 2020–50. This economic effect is equivalent to a yearly tax of 0·111% (0·085–0·141) on global GDP. China and the USA face the largest economic burdens from COPD, accounting for INT$1·363 trillion (uncertainty interval 1·034–1·801) and INT$1·037 trillion (0·868–1·175), respectively. Interpretation The macroeconomic burden of COPD is large and unequally distributed across countries, world regions, and income levels. Our study stresses the urgent need to invest in global efforts to curb the health and economic burdens of COPD. Investments in effective interventions against COPD do not represent a burden but could instead provide substantial economic returns in the foreseeable future. Funding Alexander von Humboldt Foundation, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Science, Chinese Academy of Engineering project, Chinese Academy of Medical Sciences and Peking Union Medical College project, and Horizon Europe. Translations For the Chinese and German translations of the abstract see Supplementary Materials section. INTRODUCTION Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3·3 million deaths in 2019.1 The global death toll of COPD increased by 14·1% between 2009 and 2019 because of factors such as urbanisation, air pollution, and tobacco use.1 The health burden of COPD is distributed unevenly between countries, with 90% of COPD-related deaths occurring in low-income and middle-income countries (LMICs), despite the fact that these countries only account for 83% of the global population.2 In 2019, China bore the largest COPD death toll in absolute terms, followed by India and the USA. South Korea had the highest COPD death rate, followed by Nepal, Denmark, and China.1 The incidence rate, prevalence, and mortality for COPD are shown in detail in appendix 3 (pp 2–3). In addition to causing a massive health burden, COPD also inflicts a large economic toll. The lack of information about the economic burden of COPD contributes to the insufficient attention that governments and policy makers pay to this chronic condition.3 Ministries of health and health services, particularly in LMICs, and international organisations have proposed few health policies that are aimed at preventing COPD, and there is limited access to diagnostics and little effective therapy.4 Developing comprehensive projections of the disease's economic burden and how this burden is distributed across countries is an important prerequisite for the creation and implementation of evidence-based policies to decrease morbidity and mortality from COPD. Although some studies have estimated the economic burden of COPD for one or a few countries, most studies are based on aggregating the estimated direct and indirect costs of COPD in different countries (the cost-of-illness approach), or on multiplying COPD cases and deaths by the willingness of individuals to pay to avoid risks (the value-per-statistical-life approach).2, 5, 6, 7, 8 However, these approaches do not account for economic adjustment mechanisms. First, they ignore that jobs do not remain vacant indefinitely in real-world economies because companies substitute lost labour with new workers or with physical capital (machines or robots). Second, these approaches are static and do not account for population dynamics as driven by morbidity-related and mortality-related changes, nor for the dynamics of physical capital accumulation as driven by COPD's implications for treatment costs and savings. Failing to account for these adjustment mechanisms generally leads to an overestimation of the economic burden of COPD from lost human capital. This is a common problem in projecting the economic burden of diseases and largely explains the high numbers usually found in cost-of-illness and value-per-statistical-life studies.9 Research in context Evidence before this study We searched for the terms “COPD” (or “chronic obstructive pulmonary disease”) and “economic burden” (including the variants “economic cost” and “economic loss”) in the titles and abstracts of papers included in MEDLINE, PubMed, and Google Scholar between June 1, 1960, and Dec 1, 2021, and in the references from relevant articles. The search was restricted to publications in English. Most previous studies aggregated the direct and indirect costs of chronic obstructive pulmonary disease (COPD; the cost-of-illness approach) or multiplied COPD mortality and morbidity by the willingness of individuals to pay to avoid risks (the value-per-statistical-life approach). However, both approaches ignore that jobs vacated due to illness or death do not remain vacant indefinitely because companies substitute lost labour with new workers or physical capital (machines or robots). In addition, both approaches are static and fail to account for the dynamics of morbidity-related and mortality-related population changes and for treatment costs and, thus, physical capital accumulation. Moreover, most previous studies only focused on a small number of countries (often only one). Added value of this study Using a theory-based simulation model to estimate the macroeconomic burden of COPD for 204 countries and territories, we found that COPD will cost the global economy INT$4·326 trillion (uncertainty interval 3·327–5·516; at constant 2017 prices) in 2020–50—nearly half of India's total gross domestic product (GDP) in 2019—which will be distributed unequally across regions and countries. The highest aggregate economic burdens will occur in China, the USA, and India, which have the three largest populations in the world. The per-capita burdens were highest in Ireland, Monaco, and the USA. In terms of share of GDP, the USA, North Korea, and Germany face the largest economic burdens. The economic burden of COPD was not distributed in proportion to population size or disability-adjusted life-years (DALYs): although low-income and middle-income countries accounted for an economic loss of INT$2437 billion (56·4% of the global total) from COPD, these countries represent nearly 90% of the global disease burden (in DALYs). Our findings fill several knowledge gaps. First, this study estimates for the first time (to our knowledge) the macroeconomic burden of COPD for all countries worldwide. Second, that high-income countries incur the highest macroeconomic burden of COPD in absolute terms, while low-income and middle-income